Education
About Us
Working with TipRanks
Follow Us
Novartis (CH:NOVN)
:NOVN
Earnings Data
Report Date
Jul 17, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.9Last Year’s EPS
1.97Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -0.69%
|Next Earnings Date:Jul 17, 2025
Earnings Call Sentiment|Positive
Novartis had an impressive start to the year with strong financial performance and significant product approvals, leading to an upgraded full-year guidance. However, there are ongoing challenges, particularly with the rollout of Pluvicto and the potential impacts of tariffs and geopolitical uncertainties.Company Guidance
In the recent Novartis Q1 2025 earnings call, the company reported robust financial performance with a 15% increase in sales and a 27% rise in core operating income. The core margin improved by 400 basis points to reach 42.1%, contributing to an upgrade in the full-year 2025 guidance. Notable achievements include Kisqali's 56% growth in constant currency and Entresto's 22% sales increase. The company also highlighted successful approvals for Pluvicto, Vanrafia, and Fabhalta, and significant developments in their pipeline, such as the global submission for remibrutinib and positive readouts for OAV-101 IT gene therapy. Novartis remains confident in its midterm growth outlook, targeting 5% plus sales growth and planning strategic investments in U.S. manufacturing and R&D.Strong Financial Performance
Novartis delivered a double-digit sales growth of 15% and a core operating income up 27% for Q1 2025. The core margin reached 42.1%, reflecting a 400 basis points improvement.
Significant Product Approvals
Approvals for Pluvicto, Vanrafia, and Fabhalta in their relevant indications were achieved. Additionally, a global submission for remibrutinib in CSU and OAV-101 IT gene therapy for SMA was made.
Strong Performance of Key Brands
Kisqali grew by 56%, Kesimpta by 43%, Pluvicto by 21%, and Leqvio by 72% in constant currency, showcasing robust growth across priority brands.
Upgraded Full-Year Guidance
Novartis upgraded its full-year 2025 guidance to high single-digit sales growth and low double-digit core operating income growth.
CH:NOVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:NOVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | CHF93.40 | CHF94.21 | +0.87% |
Jan 31, 2025 | CHF90.56 | CHF92.28 | +1.90% |
Oct 29, 2024 | CHF96.36 | CHF92.43 | -4.08% |
Jul 18, 2024 | CHF95.64 | CHF91.81 | -4.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novartis (CH:NOVN) report earnings?
Novartis (CH:NOVN) is schdueled to report earning on Jul 17, 2025, TBA Not Confirmed.
What is Novartis (CH:NOVN) earnings time?
Novartis (CH:NOVN) earnings time is at Jul 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novartis stock?
The P/E ratio of Novartis AG is N/A.
What is CH:NOVN EPS forecast?
CH:NOVN EPS forecast for the fiscal quarter 2025 (Q2) is 1.9.